Status:
RECRUITING
Relationship Between High-Density Lipoprotein Subtypes and Coronary Heart Disease Prognosis.
Lead Sponsor:
Beijing Tsinghua Chang Gung Hospital
Collaborating Sponsors:
Guangdong Guosheng Medical Technology
Conditions:
HDL
Coronary Heart Disease
Eligibility:
All Genders
18+ years
Brief Summary
Cardiovascular disease (CVD) is the leading cause of human mortality worldwide, imposing substantial societal and economic burdens. Traditionally, high-density lipoprotein (HDL) has been branded as th...
Eligibility Criteria
Inclusion
- The age of the patients is over 18 years old;
- Coronary artery disease was confirmed by coronary angiography.
Exclusion
- Severe valvular disease, severe myocarditis, severe hepatic and renal insufficiency, thyroid insufficiency, severe infectious or systemic inflammatory diseases, severe blood diseases, malignant tumors.
- Lack of data on HDL subtypes.
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT06190834
Start Date
December 1 2023
End Date
August 31 2026
Last Update
January 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China, 102218